• Corcept Therapeutics CFO Atabak Mokari sold 40,000 common shares on June 1 at a weighted average USD 70.
• He exercised stock options for 40,000 shares the same day at USD 19.26.
• He also acquired 1,268 shares on June 1, including 634 purchased at USD 70.44.
• 395 shares were withheld on June 2 to cover tax obligations tied to equity vesting.
• He reported 16,130 common shares owned following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-256011), on June 03, 2026, and is solely responsible for the information contained therein.